Glenmark Pharma gains on reporting 7% rise in Q2 consolidated net profit Glenmark Pharmaceuticals is currently trading at Rs. 713.00, up by 1.30 points or 0.18% from its previous closing of Rs. 711.70 on the BSE. The scrip opened at Rs. 720.05 and has touched a high and low of Rs. 722.00 and Rs. 705.90 respectively. So far 19145 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 789.40 on 09-Sep-2014 and a 52 week low of Rs. 489.10 on 27-Nov-2013. Last one week high and low of the scrip stood at Rs. 731.20 and Rs. 701.55 respectively. The current market cap of the company is Rs. 19307.02 crore. The promoters holding in the company stood at 48.31% while Institutions and Non-Institutions held 40.96% and 10.73% respectively. Glenmark Pharmaceuticals registered 9.89% rise in its net profit at Rs 116.43 crore for the quarter under review as compared to Rs 105.95 crore for the same quarter in the previous year. Total income of the company has increased 17.44% at Rs 711.75 crore for Q2FY15 as compared Rs 606.03 crore for the corresponding quarter previous year. On consolidated basis, the company’s net profit after taxes and minority interest and share of profit of associates for the quarter under review registered 6.99% growth at Rs 165.08 crore against Rs 154.30 crore in the September quarter of previous fiscal. The company’s total income has increased by 13.87% at Rs 1681.68 crore for the quarter from Rs 1476.78 crore in the similar quarter of previous year.